Arzneimittelüberempfindlichkeit

Arzneimittelüberwachung, often abbreviated as AMÜ, refers to the ongoing monitoring of pharmaceutical products after they have been approved and are available on the market. This process is crucial for ensuring the continued safety and efficacy of medicines used by the public. AMÜ systems are designed to detect and assess any potential adverse reactions or unexpected side effects that may not have been identified during the clinical trial phase.

The primary goal of Arzneimittelüberwachung is pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. This involves collecting reports of suspected adverse drug reactions from various sources, including healthcare professionals, patients, and pharmaceutical companies. These reports are then analyzed to identify patterns, trends, and potential safety signals.

Regulatory authorities, such as the European Medicines Agency (EMA) in Europe or the Food and Drug Administration (FDA) in the United States, play a central role in Arzneimittelüberwachung. They are responsible for establishing guidelines, evaluating incoming data, and taking appropriate regulatory actions if a safety issue is identified. These actions can range from updating product information and issuing safety warnings to, in rare cases, withdrawing a medicine from the market.

Arzneimittelüberwachung is a continuous and dynamic process. It helps to build a comprehensive understanding of a drug's safety profile throughout its entire lifecycle, contributing to the overall protection of public health. The effectiveness of AMÜ relies on the active participation of all stakeholders involved in the healthcare system.